A Study Evaluating Safety and Efficacy of EXP039 Treatment in NHL Subjects
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04317885 |
Recruitment Status : Unknown
Verified September 2020 by Aibin Liang,MD,Ph.D., Shanghai Tongji Hospital, Tongji University School of Medicine.
Recruitment status was: Recruiting
First Posted : March 23, 2020
Last Update Posted : September 25, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Hodgkin's B-cell Lymphoma | Biological: CD19/CD20-directed CAR-T cells | Phase 1 |
This study plans to enroll 25 patients to assess the safety and efficacy of EXP039. Subjects who meet the eligibility criteria will receive a single dose of EXP039 injection.
The study will include the following sequential phases: Screening, Pre-treatment (Cell product preparation; Lymphodepleting Chemotherapy), Treatment and follow-up.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 25 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Study Evaluating Safety and Efficacy of EXP039 Treatment in Relapsed or Refractory NHL Subjects |
Actual Study Start Date : | October 14, 2019 |
Estimated Primary Completion Date : | August 2021 |
Estimated Study Completion Date : | August 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: EXP039
Autologous EXP039 administered by intravenous (IV) infusion
|
Biological: CD19/CD20-directed CAR-T cells
Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
Other Name: EXP039 |
- Occurrence of study related adverse events [ Time Frame: 12 weeks ]Incidence and severity of Treatment emergent adverse events
- Overall response rate (ORR) [ Time Frame: 12 months ]Lugano criteria(NHL,2014).
- Duration of remission (DOR) [ Time Frame: 12 months ]
- Progression free survival (PFS) [ Time Frame: 12 months ]
- Overall survival (OS) [ Time Frame: 12 weeks, 6 months, 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 1. Volunteered to participate in this study and signed informed consent
- 2. Age 18-75 years old, male or female
- 3. Patients with relapsed or refractory B-NHL;
- 4. At least one measurable lesion (LDi ≥ 1.5 cm);
- 5. At least two weeks from the end of treatment regimen (radiation, chemotherapy, mAb, etc) to apheresis;
- 6. LVEF≥ 50% (UCG)
- 7. No active pulmonary infections, normal pulmonary function and SpO2≥92%
- 8. Laboratory criteria: ANC≥1.0×109/L; Platelets≥50×109/L; Serum total bilirubin ≤1.5x ULN; Creatinine≤ ULN; AST and ALT≤3x ULN
- 9. No contraindications of apheresis;
- 10. Expected survival ≥ 3months
- 11. ECOG score 0 or 1
- 12.The apheresis was received by laboratory and met the requirements for manufacturing CAR-T cell.
Exclusion Criteria:
- 1. Have a history of allergy to cellular products;
- 2. According to the NYHA cardiac function grading standards, patients with grade III or IV cardiac dysfunction;
- 3. A history of craniocerebral trauma, disturbance of consciousness, epilepsy, cerebrovascular ischemia, cerebrovascular hemorrhagic disease, etc.;
- 4. Patients with central nervous system involvement;
- 5. Patients with autoimmune diseases, immunodeficiency or other conditions requiring immunosuppressive therapy;
- 6. Received allogeneic hematopoietic stem cell transplantation before;
- 7. Previous use of any CAR T cell product or other genetically modified T cell therapy;
- 8. Autologous stem cell transplantation within 6 weeks before infusion;
- 9. Severe active infections (except for simple urinary tract infections, bacterial pharyngitis), or currently undergoing intravenous infusion of antibiotics, or intravenous infusion of antibiotics within 1 week prior to cell infusion. However, prophylactic antibiotic, antiviral and antifungal infection treatments are permissible;
- 10. Live vaccination within 4 weeks prior to apheresis;
- 11. People infected with HIV, HBV, HCV and TPPA/RPR, and carriers with HBV;
- 12. A history of alcohol abuse, drug use or mental illness;
-
13. Subjects who are not sterilized have any of the following conditions:
- are pregnant/lactating; or
- planned pregnancy during the trial; or
- being fertile and unable to use effective contraception;
- 14. Severe hypersensitivity to fludarabine or cyclophosphamide;
-
15. A history of other primary cancers other than the following:
- Non-melanoma tumors such as basal cell carcinoma of the skin that are cured by excision
- Cured in situ cancers such as cervical, bladder, or breast cancer
- 16. The investigators consider that the subject has other conditions that are not suitable for this trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04317885
Contact: Aibin Liang, MD, Ph.D | 0086-021-66111019 | lab7182@tongji.edu.cn | |
Contact: Ping Li, MD,Ph.D. | 0086-021-66111015 | lilyforever76@126.com |
China, Shanghai | |
Shanghai Tongji Hospital, Tongji University School of Medicine | Recruiting |
Shanghai, Shanghai, China, 200065 | |
Contact: Aibin Liang, MD, Ph.D 0086-021-66111019 lab7182@tongji.edu.cn |
Principal Investigator: | Aibin Liang, MD, Ph.D | Shanghai Tongji Hospital, Tongji University School of Medicine |
Responsible Party: | Aibin Liang,MD,Ph.D., Director, Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine |
ClinicalTrials.gov Identifier: | NCT04317885 |
Other Study ID Numbers: |
0702-015 |
First Posted: | March 23, 2020 Key Record Dates |
Last Update Posted: | September 25, 2020 |
Last Verified: | September 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |